{"protocolSection":{"identificationModule":{"nctId":"NCT02066636","orgStudyIdInfo":{"id":"CA209-153"},"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen","officialTitle":"A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen","acronym":"CheckMate153"},"statusModule":{"statusVerifiedDate":"2022-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":true,"nctId":"NCT03126643","statusForNctId":"APPROVED_FOR_MARKETING"},"startDateStruct":{"date":"2014-04-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-10-06","type":"ACTUAL"},"completionDateStruct":{"date":"2021-10-06","type":"ACTUAL"},"studyFirstSubmitDate":"2014-02-14","studyFirstSubmitQcDate":"2014-02-18","studyFirstPostDateStruct":{"date":"2014-02-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-09-29","resultsFirstSubmitQcDate":"2022-09-29","resultsFirstPostDateStruct":{"date":"2022-10-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-09-29","lastUpdatePostDateStruct":{"date":"2022-10-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer (NSCLC)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1428,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort A: Nivolumab","type":"EXPERIMENTAL","description":"Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent","interventionNames":["Drug: Nivolumab"]},{"label":"Cohort B: Nivolumab","type":"EXPERIMENTAL","description":"Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until 1 year (52 weeks).\n\nDiscontinue treatment and at progression, retreatment allowed","interventionNames":["Drug: Nivolumab"]}],"interventions":[{"type":"DRUG","name":"Nivolumab","armGroupLabels":["Cohort A: Nivolumab","Cohort B: Nivolumab"],"otherNames":["BMS-936558"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5)","description":"A treatment related adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that has a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)"}],"secondaryOutcomes":[{"measure":"Median Time to Onset of Select Adverse Events (Grade 3-5)","description":"The time from first dose to the first occurrence of any select adverse event of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)"},{"measure":"Median Time to Resolution of Select Adverse Events (Grade 3-5)","description":"The time from the onset of any select adverse event of interest to its resolution or stabilization. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)"},{"measure":"The Number of Participants Who Received Immune Modulating Medication (or Hormonal Replacement Therapy) for Any Grade Select Adverse Events","description":"The number of participants receiving medication meant to trigger an immune response for any select Adverse events of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)"},{"measure":"The Number of Participants Who Received ≥ 40 mg Prednisone Equivalents for Any Grade Select Adverse Events","description":"The number of participants receiving \\> 40mg prednisone equivalents for any select adverse event of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)"},{"measure":"The Total Duration of All Immune Modulating Medications for Any Grade Select Adverse Events","description":"The duration of time participants received medication meant to trigger an immune response for any select Adverse events of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","timeFrame":"From first dose first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)"},{"measure":"The Number of Participants With High Grade (Grade 3-4 and Grade 5) Select Adverse Events","description":"An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Target Population\n\n* Subjects with histologically-or cytologically-documented NSCLC \\[squamous (SQ) or nonsquamous (NSQ)\\] who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiotherapy for locally advanced disease)\n* Subjects must have experienced disease progression or recurrence during or after at least one systemic therapy for advanced or metastatic disease\n* Each subsequent line of therapy must be preceded by disease progression. A switch of an agent within a regimen in order to manage toxicity does not define the start of a new line of therapy\n* Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate regimen of therapy\n* Subjects who received platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy given for locally advanced disease, and developed recurrent (local or metastatic) disease within 6 months of completing therapy are eligible\n* Subjects with recurrent disease \\>6 months after platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy given for locally advanced disease, who also subsequently progressed during or after a platinum doublet-based regimen given to treat the recurrence are eligible\n* Subjects with non-squamous histology must be tested for Epithelial Growth Factor Receptor (EGFR) mutations (including, but not limited to, deletions in exon 19 and exon 21 \\[L858R\\] substitution) and Anaplastic Lymphoma Kinase (ALK) rearrangement if tests have not been previously performed. Subjects with progressive disease during or after EGFR or ALK tyrosine kinase inhibitor (TKI) regimens are eligible. Subjects are eligible if genetic test results are indeterminate or if no tumor tissue is available or accessible for testing as long as they have received one prior systemic therapy\n* Experimental therapies when given as separate regimen are considered as separate line of therapy\n* Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment performed within 28 days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST 1.1\n* Eastern Cooperative Oncology Arm (ECOG) performance status (PS)\n* PS 0 to 1\n* PS 2\n\nExclusion Criteria:\n\n1. Target Disease Exceptions\n\n   * Subjects with active central nervous system (CNS) metastases are excluded\n   * Subjects with carcinomatous meningitis\n2. Medical History and Concurrent Diseases\n\n   * Subjects with a history of interstitial lung disease\n   * Subjects with active, known or suspected autoimmune disease\n   * Subject whom participated in either arm of the following clinical trials CA209-017, CA209-057, CA209-026, and CA184-104 or received prior treatment with anti-programmed death 1 (PD-1) or anti-programmed death-ligand 1 (PDL1) experimental agents\n3. Prohibited Treatments and/or Restricted Therapies\n\n   * Ongoing or planned administration of anti-cancer therapies other than those specified in this study\n   * Use of corticosteroids or other immunosuppressive medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Southern Cancer Center Pc","city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Cancer Center Treatment Center of America","city":"Goodyear","state":"Arizona","zip":"85338","country":"United States","geoPoint":{"lat":33.43532,"lon":-112.35821}},{"facility":"Arizona Oncology Associates","city":"Phoenix","state":"Arizona","zip":"85016","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Arizona Oncology Associates","city":"Sedona","state":"Arizona","zip":"86336","country":"United States","geoPoint":{"lat":34.86974,"lon":-111.76099}},{"facility":"Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope","city":"Tucson","state":"Arizona","zip":"85704","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Comprehensive Blood And Cancer Center","city":"Bakersfield","state":"California","zip":"93309","country":"United States","geoPoint":{"lat":35.37329,"lon":-119.01871}},{"facility":"Diablo Valley Oncology","city":"Concord","state":"California","zip":"94520-2054","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"Saint Jude Heritage Medical Group Virginia K Crosson Cancer Center","city":"Fullerton","state":"California","zip":"92835","country":"United States","geoPoint":{"lat":33.87029,"lon":-117.92534}},{"facility":"Ucla Hema/Onc-Santa Monica","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Pacific Cancer Care","city":"Monterey","state":"California","zip":"93940","country":"United States","geoPoint":{"lat":36.60024,"lon":-121.89468}},{"facility":"Sutter Cancer Center","city":"Sacramento","state":"California","zip":"95816","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Local Institution","city":"San Francisco","state":"California","zip":"94117","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Central Coast Med Oncology","city":"San Luis Obispo","state":"California","zip":"93401","country":"United States","geoPoint":{"lat":35.28275,"lon":-120.65962}},{"facility":"Sansum Santa Barbara Medical Foundation Clinic","city":"Santa Barbara","state":"California","zip":"93105","country":"United States","geoPoint":{"lat":34.42083,"lon":-119.69819}},{"facility":"Central Coast Med Oncology","city":"Santa Maria","state":"California","zip":"93454","country":"United States","geoPoint":{"lat":34.95303,"lon":-120.43572}},{"facility":"Torrance Memorial Medical Center","city":"Torrance","state":"California","zip":"90505","country":"United States","geoPoint":{"lat":33.83585,"lon":-118.34063}},{"facility":"Rocky Mountain Cancer Centers","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Mountain Blue Cancer Care Center","city":"Golden","state":"Colorado","zip":"80401","country":"United States","geoPoint":{"lat":39.75554,"lon":-105.2211}},{"facility":"St. Mary's Hospital Regional Cancer Center","city":"Grand Junction","state":"Colorado","zip":"81501","country":"United States","geoPoint":{"lat":39.06387,"lon":-108.55065}},{"facility":"Eastern Ct Hem Onc Assoc","city":"Norwich","state":"Connecticut","zip":"06360","country":"United States","geoPoint":{"lat":41.52426,"lon":-72.07591}},{"facility":"Holy Cross Hospital Inc.","city":"Fort Lauderdale","state":"Florida","zip":"33308-4603","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Florida Cancer Specialists S.","city":"Fort Myers","state":"Florida","zip":"33901","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Baptist Cancer Institute","city":"Jacksonville","state":"Florida","zip":"32207","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Local Institution - 0031","city":"Lakeland","state":"Florida","zip":"33805","country":"United States","geoPoint":{"lat":28.03947,"lon":-81.9498}},{"facility":"Local Institution - 0038","city":"Miami","state":"Florida","zip":"33176","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Ocala Oncology Center","city":"Ocala","state":"Florida","zip":"34474","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"facility":"Cancer Institute Of Florida","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Memorial Cancer Institute","city":"Pemroke Pines","state":"Florida","zip":"33028","country":"United States"},{"facility":"Local Institution - 0071","city":"Pensacola","state":"Florida","zip":"32504","country":"United States","geoPoint":{"lat":30.42131,"lon":-87.21691}},{"facility":"Hematology/Oncology Associates Of The Treasure Coast","city":"Port Saint Lucie","state":"Florida","zip":"34952","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"facility":"Florida Cancer Specialists","city":"St. Petersburg","state":"Florida","zip":"33705","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Local Institution - 0108","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Space Coast Cancer Center","city":"Titusville","state":"Florida","zip":"32796","country":"United States","geoPoint":{"lat":28.61222,"lon":-80.80755}},{"facility":"University Cancer Blood Ctr","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"Piedmont Hospital","city":"Atlanta","state":"Georgia","zip":"30318","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Central Georgia Cancer Care, Pc","city":"Macon","state":"Georgia","zip":"31201","country":"United States","geoPoint":{"lat":32.84069,"lon":-83.6324}},{"facility":"Cancer Treatment Centers Of America","city":"Newnan","state":"Georgia","zip":"30265","country":"United States","geoPoint":{"lat":33.38067,"lon":-84.79966}},{"facility":"Summit Cancer Care","city":"Savannah","state":"Georgia","zip":"31405","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"facility":"Lewis Hall Singletary Oncology Center","city":"Thomasville","state":"Georgia","zip":"31792","country":"United States","geoPoint":{"lat":30.83658,"lon":-83.97878}},{"facility":"Pearlman Cancer Center","city":"Valdosta","state":"Georgia","zip":"31602","country":"United States","geoPoint":{"lat":30.83334,"lon":-83.28032}},{"facility":"University Of Illinois Cancer Center","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Illinois Cancer Specialists","city":"Niles","state":"Illinois","zip":"60714","country":"United States","geoPoint":{"lat":42.01892,"lon":-87.80284}},{"facility":"Oncology Specialists","city":"Park Ridge","state":"Illinois","zip":"60068","country":"United States","geoPoint":{"lat":42.01114,"lon":-87.84062}},{"facility":"Quincy Medical Group","city":"Quincy","state":"Illinois","zip":"62301","country":"United States","geoPoint":{"lat":39.9356,"lon":-91.40987}},{"facility":"Local Institution - 0015","city":"Skokie","state":"Illinois","zip":"60077","country":"United States","geoPoint":{"lat":42.03336,"lon":-87.73339}},{"facility":"Southern Illinois University School Of Medicine","city":"Springfield","state":"Illinois","zip":"62794-9678","country":"United States","geoPoint":{"lat":39.80172,"lon":-89.64371}},{"facility":"Local Institution - 0081","city":"Fort Wayne","state":"Indiana","zip":"46804","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Indiana University Health Melvin And Bren Simon Cancer Center","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Cancer Center Of Kansas","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Norton Cancer Center","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"University Medical Center, Inc","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"West KY Hematology Oncology Group PSC","city":"Paducah","state":"Kentucky","zip":"42003","country":"United States","geoPoint":{"lat":37.08339,"lon":-88.60005}},{"facility":"Christus Schumpert Health","city":"Shreveport","state":"Louisiana","zip":"71105","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Local Institution","city":"Brewer","state":"Maine","zip":"04412","country":"United States","geoPoint":{"lat":44.79674,"lon":-68.76142}},{"facility":"Anne Arundel Medical Center","city":"Annapolis","state":"Maryland","zip":"21401","country":"United States","geoPoint":{"lat":38.97859,"lon":-76.49184}},{"facility":"Greater Baltimore Medical Center","city":"Baltimore","state":"Maryland","zip":"21204","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Walter Reed National Mltry Medical Center","city":"Bethesda","state":"Maryland","zip":"20889","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"Maryland Oncology Hematology, P.A.","city":"Columbia","state":"Maryland","zip":"21044","country":"United States","geoPoint":{"lat":39.24038,"lon":-76.83942}},{"facility":"Bay Hematology Oncology","city":"Easton","state":"Maryland","zip":"21601","country":"United States","geoPoint":{"lat":38.77428,"lon":-76.07633}},{"facility":"Michigan Cancer Research Consortinum","city":"Ann Arbor","state":"Michigan","zip":"48016","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Cancer & Hematology Centers Of Western Michigan","city":"Grand Rapids","state":"Michigan","zip":"49503","country":"United States","geoPoint":{"lat":42.96336,"lon":-85.66809}},{"facility":"Providence Cancer Center","city":"Southfield","state":"Michigan","zip":"48075","country":"United States","geoPoint":{"lat":42.47337,"lon":-83.22187}},{"facility":"Forrest General Cancer Center","city":"Hattiesburg","state":"Mississippi","zip":"39401","country":"United States","geoPoint":{"lat":31.32712,"lon":-89.29034}},{"facility":"Jackson Oncology Associates, Pllc","city":"Jackson","state":"Mississippi","zip":"39202","country":"United States","geoPoint":{"lat":32.29876,"lon":-90.18481}},{"facility":"North Mississippi Hematology And Oncology Associates, Ltd","city":"Tupelo","state":"Mississippi","zip":"38801","country":"United States","geoPoint":{"lat":34.25807,"lon":-88.70464}},{"facility":"University Of Kansas Cancer Center","city":"North Kansas City","state":"Missouri","zip":"64116","country":"United States","geoPoint":{"lat":39.13,"lon":-94.56218}},{"facility":"Mercy Medical Research Institute","city":"Springfield","state":"Missouri","zip":"65807","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"Southeast Nebraska Hematology & Oncology Consultants, P.C.","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Nebraska Cancer Specialists","city":"Omaha","state":"Nebraska","zip":"68130","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Comprehensive Cancer Center Of Nevada","city":"Las Vegas","state":"Nevada","zip":"89119","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"VA Sierra Nevada Health Care System","city":"Reno","state":"Nevada","zip":"89502","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"Hunterdon Medical Center","city":"Flemington","state":"New Jersey","zip":"08822","country":"United States","geoPoint":{"lat":40.51233,"lon":-74.85933}},{"facility":"Atlantic Health System","city":"Summit","state":"New Jersey","zip":"07091","country":"United States","geoPoint":{"lat":40.71562,"lon":-74.36468}},{"facility":"Presbyterian Medical Group","city":"Albuquerque","state":"New Mexico","zip":"87110","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"St. Peters Hospital","city":"Albany","state":"New York","zip":"12208","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"Maimonides Medical Center","city":"Brooklyn","state":"New York","zip":"11220","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Queens Medical Associates","city":"Fresh Meadows","state":"New York","zip":"11366","country":"United States","geoPoint":{"lat":40.73482,"lon":-73.79347}},{"facility":"Broome Oncology","city":"Johnson City","state":"New York","zip":"13790","country":"United States","geoPoint":{"lat":42.11563,"lon":-75.95881}},{"facility":"Winthrop University Hospital","city":"Mineola","state":"New York","zip":"11501","country":"United States","geoPoint":{"lat":40.74927,"lon":-73.64068}},{"facility":"Mount Kisco Medical Group","city":"Mount Kisco","state":"New York","zip":"10549","country":"United States","geoPoint":{"lat":41.20426,"lon":-73.72708}},{"facility":"Columbia University Medical Center (Cumc)","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Hematology-Oncology Associates Of Rockland","city":"Nyack","state":"New York","zip":"10960","country":"United States","geoPoint":{"lat":41.09065,"lon":-73.91791}},{"facility":"Randolph Cancer Center","city":"Asheboro","state":"North Carolina","zip":"27203","country":"United States","geoPoint":{"lat":35.70791,"lon":-79.81364}},{"facility":"Southeastern Medical Oncology Center","city":"Goldsboro","state":"North Carolina","zip":"27534","country":"United States","geoPoint":{"lat":35.38488,"lon":-77.99277}},{"facility":"Moses Cone Regional Cancer Center","city":"Greensboro","state":"North Carolina","zip":"27403","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"East Carolina University Leo W. Jenkins Cancer Center","city":"Greeville","state":"North Carolina","zip":"27834","country":"United States"},{"facility":"W.G. Bill Hefner VA Medical Center","city":"Salisbury","state":"North Carolina","zip":"28144","country":"United States","geoPoint":{"lat":35.67097,"lon":-80.47423}},{"facility":"Mid Dakota Clinic, Pc","city":"Bismarck","state":"North Dakota","zip":"58501","country":"United States","geoPoint":{"lat":46.80833,"lon":-100.78374}},{"facility":"Oncology Hematology Care, Incorporated","city":"Cincinnati","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Local Institution","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Zangmeister Cancer Center","city":"Columbus","state":"Ohio","zip":"43219","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Lehigh Valley Hospital","city":"Allentown","state":"Pennsylvania","zip":"18103","country":"United States","geoPoint":{"lat":40.60843,"lon":-75.49018}},{"facility":"St. Luke's University Hospital Bethlehem","city":"Bethlehem","state":"Pennsylvania","zip":"18015","country":"United States","geoPoint":{"lat":40.62593,"lon":-75.37046}},{"facility":"Lancaster General Hospital","city":"Lancaster","state":"Pennsylvania","zip":"17604","country":"United States","geoPoint":{"lat":40.03788,"lon":-76.30551}},{"facility":"St. Mary Medical Center","city":"Langhorne","state":"Pennsylvania","zip":"19047","country":"United States","geoPoint":{"lat":40.17455,"lon":-74.92267}},{"facility":"Allegheny General Hospital","city":"Pittsburgh","state":"Pennsylvania","zip":"15212","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Charleston Hematology Oncology Associates, Pa","city":"Charleston","state":"South Carolina","zip":"29414","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"South Carolina Oncology Associates","city":"Columbia","state":"South Carolina","zip":"29210","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"Greenville Health System","city":"Greenville","state":"South Carolina","zip":"29605","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Tennessee Oncology, PLLC - SCRI - PPDS","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Cancer Care Of Wnc","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"The Jones Clinic, PC","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"The West Clinic, P.C.","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Tennessee Oncology, Pllc","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Henry-Joyce Cancer Center","city":"Nashville","state":"Tennessee","zip":"37232-0021","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Texas Oncology-Abilene","city":"Abilene","state":"Texas","zip":"79606","country":"United States","geoPoint":{"lat":32.44874,"lon":-99.73314}},{"facility":"Texas Oncology - Amarillo","city":"Amarillo","state":"Texas","zip":"79106","country":"United States","geoPoint":{"lat":35.222,"lon":-101.8313}},{"facility":"Texas Oncology","city":"Arlington","state":"Texas","zip":"76012","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"Texas Oncology-Beaumont","city":"Beaumont","state":"Texas","zip":"77702","country":"United States","geoPoint":{"lat":30.08605,"lon":-94.10185}},{"facility":"Texas Oncology","city":"Bedford","state":"Texas","zip":"76022","country":"United States","geoPoint":{"lat":32.84402,"lon":-97.14307}},{"facility":"Texas Oncology","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Oncology","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Local Institution - 0067","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Oncology","city":"Denton","state":"Texas","zip":"76201","country":"United States","geoPoint":{"lat":33.21484,"lon":-97.13307}},{"facility":"The Center For Cancer And Blood Disorders","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Northwest Cancer Center","city":"Houston","state":"Texas","zip":"77090","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Texas Oncology","city":"McAllen","state":"Texas","zip":"78503","country":"United States","geoPoint":{"lat":26.20341,"lon":-98.23001}},{"facility":"Texas Oncology","city":"Mesquite","state":"Texas","zip":"75150","country":"United States","geoPoint":{"lat":32.7668,"lon":-96.59916}},{"facility":"Texas Oncology - Odessa","city":"Midland","state":"Texas","zip":"79701","country":"United States","geoPoint":{"lat":31.99735,"lon":-102.07791}},{"facility":"Texas Oncology-Plano East","city":"Plano","state":"Texas","zip":"75075","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"facility":"Cancer Care Centers Of South Texas","city":"San Antonio","state":"Texas","zip":"78212","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Texas Cancer Center - Sherman","city":"Sherman","state":"Texas","zip":"75090","country":"United States","geoPoint":{"lat":33.63566,"lon":-96.60888}},{"facility":"Texas Oncology Cancer Care And Research Center","city":"Waco","state":"Texas","zip":"76712","country":"United States","geoPoint":{"lat":31.54933,"lon":-97.14667}},{"facility":"Utah Cancer Specialists","city":"Salt Lake City","state":"Utah","zip":"84106","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Huntsman Cancer Institute","city":"Salt Lake City","state":"Utah","zip":"84112","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"University Of Virginia Health System.","city":"Charlottesville","state":"Virginia","zip":"22908","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"Shenandoah Oncology","city":"Winchester","state":"Virginia","zip":"22601","country":"United States","geoPoint":{"lat":39.18566,"lon":-78.16333}},{"facility":"Local Institution","city":"Calgary","state":"Alberta","zip":"T2N 4N2","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Local Institution","city":"Halifax","state":"Nova Scotia","zip":"B3H 2Y9","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"Kingston General Hospital","city":"Kingston","state":"Ontario","zip":"K7L 2V7","country":"Canada","geoPoint":{"lat":44.22976,"lon":-76.48098}},{"facility":"Local Institution","city":"Ottawa","state":"Ontario","zip":"K1H 8L6","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Local Institution","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Local Institution","city":"Lévis","state":"Quebec","zip":"G6V 3Z1","country":"Canada","geoPoint":{"lat":46.80326,"lon":-71.17793}},{"facility":"Local Institution","city":"Montreal","state":"Quebec","zip":"H3T 1E2","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"referencesModule":{"references":[{"pmid":"31121324","type":"DERIVED","citation":"Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, Creelan B, Babu S, Leighl NB, Chandler JC, Couture F, Keogh G, Goss G, Daniel DB, Garon EB, Schwartzberg LS, Sen R, Korytowsky B, Li A, Aanur N, Hussein MA. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). J Thorac Oncol. 2019 Sep;14(9):1628-1639. doi: 10.1016/j.jtho.2019.05.010. Epub 2019 May 20."}],"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"http://www.BMSStudyConnect.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"After 1 year of treatment, participants who are still on treatment are randomized to Cohort A or Cohort B.","groups":[{"id":"FG000","title":"Cohort A: Nivolumab Monotherapy","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Each 14 day dosing period will constitute a cycle. After 1 year (52 weeks) of treatment all participants will continue to receive treatment until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"FG001","title":"Cohort B: Nivolumab Monotherapy","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Each 14 day dosing period will constitute a cycle. After 1 year (52 weeks) of treatment all participants will discontinue treatment. Upon progression, participants can receive retreatment."},{"id":"FG002","title":"Nivolumab Monotherapy (Not Randomized)","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Non-randomized participants were those participants who were enrolled but (after 1 year) were not randomized to either of the study cohorts (Cohort A or B)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"127"},{"groupId":"FG001","numSubjects":"125"},{"groupId":"FG002","numSubjects":"1176"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"127"},{"groupId":"FG001","numSubjects":"125"},{"groupId":"FG002","numSubjects":"1176"}]}],"dropWithdraws":[{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"700"}]},{"type":"Study drug toxicity","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"58"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"158"}]},{"type":"Adverse event unrelated to study drug","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"45"}]},{"type":"Participant request to discontinue treatment","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"70"}]},{"type":"Participant withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"61"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Maximum clinical benefit","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Poor/non-compliance","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Participant no loner meets study criteria","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"28"}]},{"type":"Administrative reasons by sponsor","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other reasons","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"50"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cohort A: Nivolumab Monotherapy","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Each 14 day dosing period will constitute a cycle. After 1 year (52 weeks) of treatment all participants will continue to receive treatment until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"BG001","title":"Cohort B: Nivolumab Monotherapy","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Each 14 day dosing period will constitute a cycle. After 1 year (52 weeks) of treatment all participants will discontinue treatment. Upon progression, participants can receive retreatment."},{"id":"BG002","title":"Nivolumab Monotherapy (Not Randomized)","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Non-randomized participants were those participants who were enrolled but (after 1 year) were not randomized to either of the study cohorts (Cohort A or B)."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"125"},{"groupId":"BG002","value":"1176"},{"groupId":"BG003","value":"1428"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66.2","spread":"10.27"},{"groupId":"BG001","value":"66.6","spread":"7.97"},{"groupId":"BG002","value":"66.1","spread":"9.82"},{"groupId":"BG003","value":"66.1","spread":"9.71"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"528"},{"groupId":"BG003","value":"657"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"648"},{"groupId":"BG003","value":"771"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"41"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"1139"},{"groupId":"BG003","value":"1381"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"5"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"42"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"84"},{"groupId":"BG003","value":"105"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"1041"},{"groupId":"BG003","value":"1266"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"8"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5)","description":"A treatment related adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that has a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","populationDescription":"All treated participants prior to randomization and treated participants randomized to Cohort A and B","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)","groups":[{"id":"OG000","title":"Cohort A: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that continued to receive treatment after completing 1 year (52 weeks) of nivolumab administered intravenously at 3 mg/kg every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"OG001","title":"Cohort B: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that discontinued treatment after 1 year (52 weeks) of receiving nivolumab administered intravenously at 3 mg/kg every two weeks. Upon progression, participants can receive retreatment."},{"id":"OG002","title":"Nivolumab Monotherapy (Pre-Randomized)","description":"All Participants that received nivolumab administered intravenously at 3 mg/kg every two weeks for up to 1 year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"1428"}]}],"classes":[{"title":"Gastrointestinal Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"20"}]}]},{"title":"Gastrointestinal Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Hepatic Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}]}]},{"title":"Hepatic Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Pulmonary Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"18"}]}]},{"title":"Pulmonary Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Renal Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"}]}]},{"title":"Renal Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Skin Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"15"}]}]},{"title":"Skin Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hypersensitivity/Infusion Reaction Events (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"}]}]},{"title":"Hypersensitivity/Infusion Reaction Events (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Endocrinopathies (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"}]}]},{"title":"Endocrinopathies (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Median Time to Onset of Select Adverse Events (Grade 3-5)","description":"The time from first dose to the first occurrence of any select adverse event of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","populationDescription":"All treated participants (both included and excluded from Cohort randomization) with at least one select adverse event from the category","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Weeks","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)","groups":[{"id":"OG000","title":"Cohort A: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that continued to receive treatment after completing 1 year (52 weeks) of nivolumab administered intravenously at 3 mg/kg every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"OG001","title":"Cohort B: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that discontinued treatment after 1 year (52 weeks) of receiving nivolumab administered intravenously at 3 mg/kg every two weeks. Upon progression, participants can receive retreatment."},{"id":"OG002","title":"Nivolumab Monotherapy (Not Randomized)","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Non-randomized participants were those participants who were enrolled but (after 1 year) were not randomized to either of the study cohorts (Cohort A or B)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"38"}]}],"classes":[{"title":"Endocrine Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.14","lowerLimit":"11.0","upperLimit":"45.4"},{"groupId":"OG001","value":"25.3","lowerLimit":"25.3","upperLimit":"25.3"},{"groupId":"OG002","value":"11.14","lowerLimit":"5.6","upperLimit":"42.7"}]}]},{"title":"Gastrointestinal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.71","lowerLimit":"22.7","upperLimit":"272.3"},{"groupId":"OG001","value":"49.21","lowerLimit":"33.9","upperLimit":"59.4"},{"groupId":"OG002","value":"17.86","lowerLimit":"0.7","upperLimit":"46.1"}]}]},{"title":"Hepatic Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.50","lowerLimit":"16.4","upperLimit":"152.6"},{"groupId":"OG002","value":"4.14","lowerLimit":"1.3","upperLimit":"42.1"}]}]},{"title":"Pulmonary Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"156.21","lowerLimit":"97.9","upperLimit":"214.6"},{"groupId":"OG002","value":"7.79","lowerLimit":"0.6","upperLimit":"35.9"}]}]},{"title":"Renal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"108.00","lowerLimit":"35.9","upperLimit":"180.1"},{"groupId":"OG001","value":"15.1","lowerLimit":"15.1","upperLimit":"15.1"},{"groupId":"OG002","value":"6.71","lowerLimit":"3.0","upperLimit":"49.6"}]}]},{"title":"Skin Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.14","lowerLimit":"0.1","upperLimit":"48.1"},{"groupId":"OG001","value":"18.14","lowerLimit":"16.1","upperLimit":"20.1"},{"groupId":"OG002","value":"10.57","lowerLimit":"2.1","upperLimit":"51.6"}]}]},{"title":"Hypersensitivity/Infusion Reaction","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"42.00","lowerLimit":"42.0","upperLimit":"42.0"},{"groupId":"OG002","value":"2.36","lowerLimit":"2.0","upperLimit":"8.1"}]}]}]},{"type":"SECONDARY","title":"Median Time to Resolution of Select Adverse Events (Grade 3-5)","description":"The time from the onset of any select adverse event of interest to its resolution or stabilization. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","populationDescription":"All treated participants (both included and excluded from Cohort randomization) with at least one select adverse event from the category","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Weeks","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)","groups":[{"id":"OG000","title":"Cohort A: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that continued to receive treatment after completing 1 year (52 weeks) of nivolumab administered intravenously at 3 mg/kg every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"OG001","title":"Cohort B: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that discontinued treatment after 1 year (52 weeks) of receiving nivolumab administered intravenously at 3 mg/kg every two weeks. Upon progression, participants can receive retreatment."},{"id":"OG002","title":"Nivolumab Monotherapy (Not Randomized)","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Non-randomized participants were those participants who were enrolled but (after 1 year) were not randomized to either of the study cohorts (Cohort A or B)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"38"}]}],"classes":[{"title":"Endocrine Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.43","lowerLimit":"0.4","upperLimit":"36.1"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"1.0"},{"groupId":"OG002","value":"3.57","lowerLimit":"0.9","upperLimit":"4.4"}]}]},{"title":"Gastrointestinal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.79","lowerLimit":"0.4","upperLimit":"29.4"},{"groupId":"OG001","value":"1.50","lowerLimit":"0.3","upperLimit":"3.0"},{"groupId":"OG002","value":"1.86","lowerLimit":"0.6","upperLimit":"27.1"}]}]},{"title":"Hepatic Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","lowerLimit":"0.4","upperLimit":"2.3"},{"groupId":"OG002","value":"12.57","lowerLimit":"0.1","upperLimit":"36.9"}]}]},{"title":"Pulmonary Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","lowerLimit":"0.7","upperLimit":"1.6"},{"groupId":"OG002","value":"2.57","lowerLimit":"0.1","upperLimit":"30.3"}]}]},{"title":"Renal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","lowerLimit":"0.4","upperLimit":"0.9"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.9","upperLimit":"1.9"},{"groupId":"OG002","value":"1.29","lowerLimit":"0.3","upperLimit":"5.1"}]}]},{"title":"Skin Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","lowerLimit":"2.1","upperLimit":"32.9"},{"groupId":"OG001","value":"2.43","lowerLimit":"2.1","upperLimit":"2.7"},{"groupId":"OG002","value":"9.14","lowerLimit":"1.0","upperLimit":"234"}]}]},{"title":"Hypersensitivity/Infusion Reaction","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.1","lowerLimit":"0.1","upperLimit":"0.1"},{"groupId":"OG002","value":"0.1","lowerLimit":"0.1","upperLimit":"0.1"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Who Received Immune Modulating Medication (or Hormonal Replacement Therapy) for Any Grade Select Adverse Events","description":"The number of participants receiving medication meant to trigger an immune response for any select Adverse events of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","populationDescription":"All treated participants (both included and excluded from Cohort randomization) with at least one select adverse event from the category","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)","groups":[{"id":"OG000","title":"Cohort A: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that continued to receive treatment after completing 1 year (52 weeks) of nivolumab administered intravenously at 3 mg/kg every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"OG001","title":"Cohort B: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that discontinued treatment after 1 year (52 weeks) of receiving nivolumab administered intravenously at 3 mg/kg every two weeks. Upon progression, participants can receive retreatment."},{"id":"OG002","title":"Nivolumab Monotherapy (Not Randomized)","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Non-randomized participants were those participants who were enrolled but (after 1 year) were not randomized to either of the study cohorts (Cohort A or B)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"314"}]}],"classes":[{"title":"Endocrine Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"209"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"15"}]}]},{"title":"Gastrointestinal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"35"}]}]},{"title":"Hepatic Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"13"}]}]},{"title":"Pulmonary Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"42"}]}]},{"title":"Renal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"12"}]}]},{"title":"Skin Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"314"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"113"}]}]},{"title":"Hypersensitivity/Infusion Reaction","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"14"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Who Received ≥ 40 mg Prednisone Equivalents for Any Grade Select Adverse Events","description":"The number of participants receiving \\> 40mg prednisone equivalents for any select adverse event of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","populationDescription":"All treated participants (both included and excluded from Cohort randomization) with at least one select adverse event from the category","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)","groups":[{"id":"OG000","title":"Cohort A: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that continued to receive treatment after completing 1 year (52 weeks) of nivolumab administered intravenously at 3 mg/kg every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"OG001","title":"Cohort B: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that discontinued treatment after 1 year (52 weeks) of receiving nivolumab administered intravenously at 3 mg/kg every two weeks. Upon progression, participants can receive retreatment."},{"id":"OG002","title":"Nivolumab Monotherapy (Not Randomized)","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Non-randomized participants were those participants who were enrolled but (after 1 year) were not randomized to either of the study cohorts (Cohort A or B)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"314"}]}],"classes":[{"title":"Endocrine Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"209"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}]}]},{"title":"Gastrointestinal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"21"}]}]},{"title":"Hepatic Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"}]}]},{"title":"Pulmonary Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"31"}]}]},{"title":"Renal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"}]}]},{"title":"Skin Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"314"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"14"}]}]},{"title":"Hypersensitivity/Infusion Reaction","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]}]},{"type":"SECONDARY","title":"The Total Duration of All Immune Modulating Medications for Any Grade Select Adverse Events","description":"The duration of time participants received medication meant to trigger an immune response for any select Adverse events of interest. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","populationDescription":"All treated participants (both included and excluded from Cohort randomization) with at least one select adverse event from the category","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Weeks","timeFrame":"From first dose first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)","groups":[{"id":"OG000","title":"Cohort A: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that continued to receive treatment after completing 1 year (52 weeks) of nivolumab administered intravenously at 3 mg/kg every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"OG001","title":"Cohort B: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that discontinued treatment after 1 year (52 weeks) of receiving nivolumab administered intravenously at 3 mg/kg every two weeks. Upon progression, participants can receive retreatment."},{"id":"OG002","title":"Nivolumab Monotherapy (Not Randomized)","description":"Participants receive nivolumab administered intravenously at 3 mg/kg every two weeks. Non-randomized participants were those participants who were enrolled but (after 1 year) were not randomized to either of the study cohorts (Cohort A or B)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"314"}]}],"classes":[{"title":"Endocrine Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"209"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG001","value":"82.57","lowerLimit":"2.0","upperLimit":"163.1"},{"groupId":"OG002","value":"2.57","lowerLimit":"0.1","upperLimit":"76.0"}]}]},{"title":"Gastrointestinal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.43","lowerLimit":"2.4","upperLimit":"8.1"},{"groupId":"OG001","value":"2.50","lowerLimit":"1.6","upperLimit":"3.4"},{"groupId":"OG002","value":"3.79","lowerLimit":"0.4","upperLimit":"32.6"}]}]},{"title":"Hepatic Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG002","value":"5.0","lowerLimit":"0.4","upperLimit":"14.0"}]}]},{"title":"Pulmonary Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.57","lowerLimit":"0.3","upperLimit":"27.1"},{"groupId":"OG001","value":"2.86","lowerLimit":"1.1","upperLimit":"5.9"},{"groupId":"OG002","value":"3.57","lowerLimit":"0.1","upperLimit":"26.1"}]}]},{"title":"Renal Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.7","upperLimit":"0.7"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG002","value":"2.57","lowerLimit":"0.3","upperLimit":"16.9"}]}]},{"title":"Skin Adverse Event","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"314"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.14","lowerLimit":"0.9","upperLimit":"151.0"},{"groupId":"OG001","value":"6.71","lowerLimit":"1.0","upperLimit":"16.4"},{"groupId":"OG002","value":"4.07","lowerLimit":"0.1","upperLimit":"80.1"}]}]},{"title":"Hypersensitivity/Infusion Reaction","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.71","lowerLimit":"1.0","upperLimit":"4.4"},{"groupId":"OG001","value":"2.0","lowerLimit":"2.0","upperLimit":"2.0"},{"groupId":"OG002","value":"0.14","lowerLimit":"0.1","upperLimit":"2.1"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With High Grade (Grade 3-4 and Grade 5) Select Adverse Events","description":"An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.","populationDescription":"All treated participants prior to randomization and treated participants randomized to Cohort A and B","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)","groups":[{"id":"OG000","title":"Cohort A: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that continued to receive treatment after completing 1 year (52 weeks) of nivolumab administered intravenously at 3 mg/kg every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent."},{"id":"OG001","title":"Cohort B: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that discontinued treatment after 1 year (52 weeks) of receiving nivolumab administered intravenously at 3 mg/kg every two weeks. Upon progression, participants can receive retreatment."},{"id":"OG002","title":"Nivolumab Monotherapy (Pre-Randomized)","description":"All Participants that received nivolumab administered intravenously at 3 mg/kg every two weeks for up to 1 year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"1428"}]}],"classes":[{"title":"Gastrointestinal Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"35"}]}]},{"title":"Gastrointestinal Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Hepatic Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"34"}]}]},{"title":"Hepatic Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Pulmonary Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"31"}]}]},{"title":"Pulmonary Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"}]}]},{"title":"Renal Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"14"}]}]},{"title":"Renal Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Skin Adverse Event (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"18"}]}]},{"title":"Skin Adverse Event (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hypersensitivity/Infusion Reaction Events (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}]}]},{"title":"Hypersensitivity/Infusion Reaction Events (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Endocrinopathies (Grade3-4)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"}]}]},{"title":"Endocrinopathies (Grade 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Participants were assessed for all-cause mortality from their first dose to study completion (up to approximately 90 months) . SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 88 months).","description":"Post-Randomization indicates only data after randomization is summarized (applies to Cohort A and B). Pre-Randomized indicates only data before randomization is summarized (applies to all treated participants). Total indicates data is summarized throughout the full duration of the study (applies to all treated participants).","eventGroups":[{"id":"EG000","title":"Cohort A: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that continued to receive treatment after completing 1 year (52 weeks) of nivolumab administered intravenously at 3 mg/kg every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent.","deathsNumAffected":63,"deathsNumAtRisk":127,"seriousNumAffected":57,"seriousNumAtRisk":127,"otherNumAffected":101,"otherNumAtRisk":127},{"id":"EG001","title":"Cohort B: Nivolumab Monotherapy (Post-Randomization)","description":"All participants that discontinued treatment after 1 year (52 weeks) of receiving nivolumab administered intravenously at 3 mg/kg every two weeks. Upon progression, participants can receive retreatment.","deathsNumAffected":77,"deathsNumAtRisk":125,"seriousNumAffected":52,"seriousNumAtRisk":125,"otherNumAffected":82,"otherNumAtRisk":125},{"id":"EG002","title":"Nivolumab Monotherapy (Pre-Randomized)","description":"All Participants that received nivolumab administered intravenously at 3 mg/kg every two weeks for up to 1 year.","deathsNumAffected":1040,"deathsNumAtRisk":1428,"seriousNumAffected":870,"seriousNumAtRisk":1428,"otherNumAffected":1287,"otherNumAtRisk":1428},{"id":"EG003","title":"Nivolumab Monotherapy (Total)","description":"All Participants that received nivolumab administered intravenously at 3 mg/kg every two weeks regardless of continuation or discontinuation of treatment.","deathsNumAffected":1180,"deathsNumAtRisk":1428,"seriousNumAffected":918,"seriousNumAtRisk":1428,"otherNumAffected":1306,"otherNumAtRisk":1428}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":125},{"groupId":"EG002","numAffected":12,"numAtRisk":1428},{"groupId":"EG003","numAffected":13,"numAtRisk":1428}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":7,"numAtRisk":1428},{"groupId":"EG003","numAffected":7,"numAtRisk":1428}]},{"term":"Hypercoagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":5,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Thrombotic thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":5,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":12,"numAtRisk":1428},{"groupId":"EG003","numAffected":14,"numAtRisk":1428}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Atrial thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Cardiac disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":6,"numAtRisk":1428},{"groupId":"EG003","numAffected":7,"numAtRisk":1428}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":7,"numAtRisk":1428},{"groupId":"EG003","numAffected":8,"numAtRisk":1428}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":11,"numAtRisk":1428},{"groupId":"EG003","numAffected":12,"numAtRisk":1428}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":5,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Vestibular disorder","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Hypercalcaemia of malignancy","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Ocular myasthenia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":17,"numAtRisk":1428},{"groupId":"EG003","numAffected":18,"numAtRisk":1428}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":7,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":8,"numAtRisk":1428},{"groupId":"EG003","numAffected":8,"numAtRisk":1428}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":13,"numAtRisk":1428},{"groupId":"EG003","numAffected":14,"numAtRisk":1428}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Duodenal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Duodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":8,"numAtRisk":1428},{"groupId":"EG003","numAffected":8,"numAtRisk":1428}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Enterocolonic fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Gastrointestinal angiectasia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":6,"numAtRisk":1428},{"groupId":"EG003","numAffected":6,"numAtRisk":1428}]},{"term":"Gastrointestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Incarcerated umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":12,"numAtRisk":1428},{"groupId":"EG003","numAffected":13,"numAtRisk":1428}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Oesophageal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Oesophageal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pancreatitis chronic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Proctalgia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Retroperitoneal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Volvulus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":8,"numAtRisk":1428},{"groupId":"EG003","numAffected":8,"numAtRisk":1428}]},{"term":"Catheter site injury","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":14,"numAtRisk":1428},{"groupId":"EG003","numAffected":14,"numAtRisk":1428}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":9,"numAtRisk":1428}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Infusion site extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Localised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":15,"numAtRisk":1428},{"groupId":"EG003","numAffected":15,"numAtRisk":1428}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Physical deconditioning","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":125},{"groupId":"EG002","numAffected":8,"numAtRisk":1428},{"groupId":"EG003","numAffected":8,"numAtRisk":1428}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Autoimmune cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Biliary obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hepatitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Abscess intestinal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Abscess oral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":6,"numAtRisk":1428}]},{"term":"Catheter site cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Clostridium difficile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cryptococcosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Enterobacter pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Enterococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Escherichia sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Groin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Papilloma viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pneumococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":125},{"groupId":"EG002","numAffected":118,"numAtRisk":1428},{"groupId":"EG003","numAffected":137,"numAtRisk":1428}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":8,"numAtRisk":1428},{"groupId":"EG003","numAffected":8,"numAtRisk":1428}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Pneumonia haemophilus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pneumonia mycoplasmal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pneumonia necrotising","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pneumonia pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pneumonia staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Pneumonia streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pseudomonas infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":125},{"groupId":"EG002","numAffected":22,"numAtRisk":1428},{"groupId":"EG003","numAffected":26,"numAtRisk":1428}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":8,"numAtRisk":1428},{"groupId":"EG003","numAffected":9,"numAtRisk":1428}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Vascular device infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Wound infection staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Fractured sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":5,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Ilium fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Post-traumatic pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Procedural pneumothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Product administration error","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Ulna fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Brain natriuretic peptide increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Influenza A virus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Staphylococcus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Troponin I increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":33,"numAtRisk":1428},{"groupId":"EG003","numAffected":35,"numAtRisk":1428}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":8,"numAtRisk":1428},{"groupId":"EG003","numAffected":8,"numAtRisk":1428}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hypervolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":5,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":8,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":6,"numAtRisk":1428},{"groupId":"EG003","numAffected":6,"numAtRisk":1428}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":11,"numAtRisk":1428},{"groupId":"EG003","numAffected":12,"numAtRisk":1428}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":6,"numAtRisk":1428},{"groupId":"EG003","numAffected":6,"numAtRisk":1428}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Intervertebral disc degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":5,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":5,"numAtRisk":1428},{"groupId":"EG003","numAffected":6,"numAtRisk":1428}]},{"term":"Polymyositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Brain neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":7,"numAtRisk":1428},{"groupId":"EG003","numAffected":7,"numAtRisk":1428}]},{"term":"Diffuse large B-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Intraductal proliferative breast lesion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Malignant melanoma in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":127},{"groupId":"EG001","numAffected":15,"numAtRisk":125},{"groupId":"EG002","numAffected":509,"numAtRisk":1428},{"groupId":"EG003","numAffected":521,"numAtRisk":1428}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":6,"numAtRisk":1428},{"groupId":"EG003","numAffected":6,"numAtRisk":1428}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Metastases to spine","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Myelodysplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":6,"numAtRisk":1428},{"groupId":"EG003","numAffected":6,"numAtRisk":1428}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Neuroendocrine carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Pericardial effusion malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Respiratory papilloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Second primary malignancy","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Central nervous system haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cerebellar stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cerebrospinal fluid leakage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Cervical radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Dyskinesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Hepatic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Ischaemic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Lacunar stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Metabolic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":12,"numAtRisk":1428},{"groupId":"EG003","numAffected":14,"numAtRisk":1428}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":9,"numAtRisk":1428}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":11,"numAtRisk":1428}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Device malfunction","organSystem":"Product Issues","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":11,"numAtRisk":1428},{"groupId":"EG003","numAffected":12,"numAtRisk":1428}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":9,"numAtRisk":1428},{"groupId":"EG003","numAffected":9,"numAtRisk":1428}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":15,"numAtRisk":1428},{"groupId":"EG003","numAffected":15,"numAtRisk":1428}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Renal pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Adnexal torsion","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":125},{"groupId":"EG002","numAffected":18,"numAtRisk":1428},{"groupId":"EG003","numAffected":18,"numAtRisk":1428}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":3,"numAtRisk":1428},{"groupId":"EG003","numAffected":3,"numAtRisk":1428}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Bronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Bronchopleural fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":125},{"groupId":"EG002","numAffected":27,"numAtRisk":1428},{"groupId":"EG003","numAffected":31,"numAtRisk":1428}]},{"term":"Chronic respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":5,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":91,"numAtRisk":1428},{"groupId":"EG003","numAffected":92,"numAtRisk":1428}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":10,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":16,"numAtRisk":1428},{"groupId":"EG003","numAffected":17,"numAtRisk":1428}]},{"term":"Laryngeal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Lung opacity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":125},{"groupId":"EG002","numAffected":37,"numAtRisk":1428},{"groupId":"EG003","numAffected":38,"numAtRisk":1428}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":23,"numAtRisk":1428},{"groupId":"EG003","numAffected":24,"numAtRisk":1428}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":10,"numAtRisk":1428},{"groupId":"EG003","numAffected":10,"numAtRisk":1428}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":40,"numAtRisk":1428},{"groupId":"EG003","numAffected":43,"numAtRisk":1428}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pulmonary sarcoidosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Respiratory disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":5,"numAtRisk":1428}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":22,"numAtRisk":1428},{"groupId":"EG003","numAffected":23,"numAtRisk":1428}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Pemphigoid","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":0,"numAtRisk":1428}]},{"term":"Psoriasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Aortic stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":16,"numAtRisk":1428},{"groupId":"EG003","numAffected":17,"numAtRisk":1428}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":7,"numAtRisk":1428},{"groupId":"EG003","numAffected":7,"numAtRisk":1428}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Hypertensive urgency","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":7,"numAtRisk":1428},{"groupId":"EG003","numAffected":7,"numAtRisk":1428}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":0,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Peripheral embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":2,"numAtRisk":1428},{"groupId":"EG003","numAffected":2,"numAtRisk":1428}]},{"term":"Shock haemorrhagic","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":1,"numAtRisk":1428},{"groupId":"EG003","numAffected":1,"numAtRisk":1428}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":4,"numAtRisk":1428},{"groupId":"EG003","numAffected":4,"numAtRisk":1428}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":125},{"groupId":"EG002","numAffected":208,"numAtRisk":1428},{"groupId":"EG003","numAffected":222,"numAtRisk":1428}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":129,"numAtRisk":1428},{"groupId":"EG003","numAffected":136,"numAtRisk":1428}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":125},{"groupId":"EG002","numAffected":117,"numAtRisk":1428},{"groupId":"EG003","numAffected":133,"numAtRisk":1428}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":127},{"groupId":"EG001","numAffected":6,"numAtRisk":125},{"groupId":"EG002","numAffected":274,"numAtRisk":1428},{"groupId":"EG003","numAffected":290,"numAtRisk":1428}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":127},{"groupId":"EG001","numAffected":17,"numAtRisk":125},{"groupId":"EG002","numAffected":275,"numAtRisk":1428},{"groupId":"EG003","numAffected":292,"numAtRisk":1428}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":127},{"groupId":"EG001","numAffected":9,"numAtRisk":125},{"groupId":"EG002","numAffected":332,"numAtRisk":1428},{"groupId":"EG003","numAffected":352,"numAtRisk":1428}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":125},{"groupId":"EG002","numAffected":191,"numAtRisk":1428},{"groupId":"EG003","numAffected":207,"numAtRisk":1428}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":73,"numAtRisk":1428},{"groupId":"EG003","numAffected":79,"numAtRisk":1428}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":127},{"groupId":"EG001","numAffected":17,"numAtRisk":125},{"groupId":"EG002","numAffected":516,"numAtRisk":1428},{"groupId":"EG003","numAffected":544,"numAtRisk":1428}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":127},{"groupId":"EG001","numAffected":3,"numAtRisk":125},{"groupId":"EG002","numAffected":84,"numAtRisk":1428},{"groupId":"EG003","numAffected":94,"numAtRisk":1428}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":127},{"groupId":"EG001","numAffected":9,"numAtRisk":125},{"groupId":"EG002","numAffected":180,"numAtRisk":1428},{"groupId":"EG003","numAffected":197,"numAtRisk":1428}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":125},{"groupId":"EG002","numAffected":123,"numAtRisk":1428},{"groupId":"EG003","numAffected":143,"numAtRisk":1428}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":125},{"groupId":"EG002","numAffected":50,"numAtRisk":1428},{"groupId":"EG003","numAffected":64,"numAtRisk":1428}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":127},{"groupId":"EG001","numAffected":14,"numAtRisk":125},{"groupId":"EG002","numAffected":89,"numAtRisk":1428},{"groupId":"EG003","numAffected":102,"numAtRisk":1428}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":59,"numAtRisk":1428},{"groupId":"EG003","numAffected":65,"numAtRisk":1428}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":127},{"groupId":"EG001","numAffected":15,"numAtRisk":125},{"groupId":"EG002","numAffected":128,"numAtRisk":1428},{"groupId":"EG003","numAffected":153,"numAtRisk":1428}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":127},{"groupId":"EG001","numAffected":11,"numAtRisk":125},{"groupId":"EG002","numAffected":60,"numAtRisk":1428},{"groupId":"EG003","numAffected":75,"numAtRisk":1428}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":127},{"groupId":"EG001","numAffected":10,"numAtRisk":125},{"groupId":"EG002","numAffected":54,"numAtRisk":1428},{"groupId":"EG003","numAffected":65,"numAtRisk":1428}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":65,"numAtRisk":1428},{"groupId":"EG003","numAffected":76,"numAtRisk":1428}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":127},{"groupId":"EG001","numAffected":20,"numAtRisk":125},{"groupId":"EG002","numAffected":182,"numAtRisk":1428},{"groupId":"EG003","numAffected":192,"numAtRisk":1428}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":39,"numAtRisk":1428},{"groupId":"EG003","numAffected":48,"numAtRisk":1428}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":127},{"groupId":"EG001","numAffected":13,"numAtRisk":125},{"groupId":"EG002","numAffected":313,"numAtRisk":1428},{"groupId":"EG003","numAffected":336,"numAtRisk":1428}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":127},{"groupId":"EG001","numAffected":3,"numAtRisk":125},{"groupId":"EG002","numAffected":127,"numAtRisk":1428},{"groupId":"EG003","numAffected":134,"numAtRisk":1428}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":61,"numAtRisk":1428},{"groupId":"EG003","numAffected":68,"numAtRisk":1428}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":127},{"groupId":"EG001","numAffected":9,"numAtRisk":125},{"groupId":"EG002","numAffected":126,"numAtRisk":1428},{"groupId":"EG003","numAffected":138,"numAtRisk":1428}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":127},{"groupId":"EG001","numAffected":8,"numAtRisk":125},{"groupId":"EG002","numAffected":149,"numAtRisk":1428},{"groupId":"EG003","numAffected":162,"numAtRisk":1428}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":125},{"groupId":"EG002","numAffected":97,"numAtRisk":1428},{"groupId":"EG003","numAffected":102,"numAtRisk":1428}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":127},{"groupId":"EG001","numAffected":18,"numAtRisk":125},{"groupId":"EG002","numAffected":284,"numAtRisk":1428},{"groupId":"EG003","numAffected":314,"numAtRisk":1428}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":127},{"groupId":"EG001","numAffected":11,"numAtRisk":125},{"groupId":"EG002","numAffected":189,"numAtRisk":1428},{"groupId":"EG003","numAffected":211,"numAtRisk":1428}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":44,"numAtRisk":1428},{"groupId":"EG003","numAffected":57,"numAtRisk":1428}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":127},{"groupId":"EG001","numAffected":8,"numAtRisk":125},{"groupId":"EG002","numAffected":74,"numAtRisk":1428},{"groupId":"EG003","numAffected":82,"numAtRisk":1428}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":127},{"groupId":"EG001","numAffected":2,"numAtRisk":125},{"groupId":"EG002","numAffected":90,"numAtRisk":1428},{"groupId":"EG003","numAffected":102,"numAtRisk":1428}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":127},{"groupId":"EG001","numAffected":6,"numAtRisk":125},{"groupId":"EG002","numAffected":60,"numAtRisk":1428},{"groupId":"EG003","numAffected":67,"numAtRisk":1428}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":125},{"groupId":"EG002","numAffected":44,"numAtRisk":1428},{"groupId":"EG003","numAffected":50,"numAtRisk":1428}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":127},{"groupId":"EG001","numAffected":8,"numAtRisk":125},{"groupId":"EG002","numAffected":101,"numAtRisk":1428},{"groupId":"EG003","numAffected":112,"numAtRisk":1428}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":125},{"groupId":"EG002","numAffected":140,"numAtRisk":1428},{"groupId":"EG003","numAffected":156,"numAtRisk":1428}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":127},{"groupId":"EG001","numAffected":8,"numAtRisk":125},{"groupId":"EG002","numAffected":140,"numAtRisk":1428},{"groupId":"EG003","numAffected":161,"numAtRisk":1428}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":127},{"groupId":"EG001","numAffected":3,"numAtRisk":125},{"groupId":"EG002","numAffected":96,"numAtRisk":1428},{"groupId":"EG003","numAffected":106,"numAtRisk":1428}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":125},{"groupId":"EG002","numAffected":71,"numAtRisk":1428},{"groupId":"EG003","numAffected":75,"numAtRisk":1428}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":125},{"groupId":"EG002","numAffected":128,"numAtRisk":1428},{"groupId":"EG003","numAffected":147,"numAtRisk":1428}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":127},{"groupId":"EG001","numAffected":9,"numAtRisk":125},{"groupId":"EG002","numAffected":41,"numAtRisk":1428},{"groupId":"EG003","numAffected":54,"numAtRisk":1428}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":127},{"groupId":"EG001","numAffected":22,"numAtRisk":125},{"groupId":"EG002","numAffected":302,"numAtRisk":1428},{"groupId":"EG003","numAffected":331,"numAtRisk":1428}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":127},{"groupId":"EG001","numAffected":17,"numAtRisk":125},{"groupId":"EG002","numAffected":339,"numAtRisk":1428},{"groupId":"EG003","numAffected":359,"numAtRisk":1428}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":127},{"groupId":"EG001","numAffected":8,"numAtRisk":125},{"groupId":"EG002","numAffected":82,"numAtRisk":1428},{"groupId":"EG003","numAffected":88,"numAtRisk":1428}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":49,"numAtRisk":1428},{"groupId":"EG003","numAffected":58,"numAtRisk":1428}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":127},{"groupId":"EG001","numAffected":1,"numAtRisk":125},{"groupId":"EG002","numAffected":51,"numAtRisk":1428},{"groupId":"EG003","numAffected":55,"numAtRisk":1428}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":33,"numAtRisk":1428},{"groupId":"EG003","numAffected":42,"numAtRisk":1428}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":127},{"groupId":"EG001","numAffected":7,"numAtRisk":125},{"groupId":"EG002","numAffected":94,"numAtRisk":1428},{"groupId":"EG003","numAffected":105,"numAtRisk":1428}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":127},{"groupId":"EG001","numAffected":3,"numAtRisk":125},{"groupId":"EG002","numAffected":21,"numAtRisk":1428},{"groupId":"EG003","numAffected":30,"numAtRisk":1428}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":125},{"groupId":"EG002","numAffected":71,"numAtRisk":1428},{"groupId":"EG003","numAffected":80,"numAtRisk":1428}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":125},{"groupId":"EG002","numAffected":119,"numAtRisk":1428},{"groupId":"EG003","numAffected":127,"numAtRisk":1428}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":125},{"groupId":"EG002","numAffected":98,"numAtRisk":1428},{"groupId":"EG003","numAffected":108,"numAtRisk":1428}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":127},{"groupId":"EG001","numAffected":4,"numAtRisk":125},{"groupId":"EG002","numAffected":62,"numAtRisk":1428},{"groupId":"EG003","numAffected":72,"numAtRisk":1428}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":127},{"groupId":"EG001","numAffected":0,"numAtRisk":125},{"groupId":"EG002","numAffected":37,"numAtRisk":1428},{"groupId":"EG003","numAffected":42,"numAtRisk":1428}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":127},{"groupId":"EG001","numAffected":6,"numAtRisk":125},{"groupId":"EG002","numAffected":56,"numAtRisk":1428},{"groupId":"EG003","numAffected":64,"numAtRisk":1428}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":127},{"groupId":"EG001","numAffected":5,"numAtRisk":125},{"groupId":"EG002","numAffected":70,"numAtRisk":1428},{"groupId":"EG003","numAffected":79,"numAtRisk":1428}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@bms.com","phone":"Please email"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2017-12-01","uploadDate":"2022-09-29T17:04","filename":"Prot_SAP_000.pdf","size":8135808}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}